Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Rapid Diagnosis Possible at POC

By Labmedica International staff writers
Posted on 05 Mar 2013
Image: The hand-held cobas h 232 is suitable for use in different clinical settings, from the General Practitioner’s office to the Emergency Room (Photo courtesy of Roche).
Image: The hand-held cobas h 232 is suitable for use in different clinical settings, from the General Practitioner’s office to the Emergency Room (Photo courtesy of Roche).
A versatile handheld device enables rapid diagnosis at point of care (POC).

In hospitals, Roche's (Burgess, United Kingdom) products can support laboratory services by providing accurate diagnosis of patient samples and enabling rapid diagnosis of medical conditions in the emergency ward, intensive care, and in the operating theatre.

Forth Valley Royal Hospital (United Kingdom) has reduced lengths of stay and ward admissions for patients presenting with chest pain, as well as ensuring rapid referral for patients with positive findings, through the introduction of a Chest Pain Assessment Unit (CPAU). This unit provides patient care and rapid access to diagnostic testing, including Troponin T testing, using the Roche point of care (POC) cardiac marker system, cobas h 232.

“Prior to opening the CPAU, patients at low risk of Acute Coronary Syndrome (ACS) were spending a long time in hospital unnecessarily, often overnight, while ACS was ruled out,” explained nurse consultant-acute medicine, Sharon Oswald. “To obtain real-time results that enable rapid decisions to be made, we introduced the Roche cobas h 232 system for point-of-care Troponin T testing. The cobas h 232 has had a huge impact on the service. Before we introduced it, Troponin T tests were batched and performed four times per day in the laboratory. There were sometimes delays in getting the bloods to the laboratory and then in getting results back. Now, with the cobas h 232 systems, we are able to obtain results in real time, which allows faster decision making.”

“The cobas h 232 system is very sensitive,” Sharon added. “A six month comparative evaluation demonstrated that we were getting comparable results to the laboratory method. We still send positives to the laboratory for confirmation but negative results do not require further confirmation. This means [we can exclude] ACS more quickly, allowing earlier discharge. Patients that require further investigation or care can be referred immediately or given a planned return appointment.”

Related Links:
Roche
Forth Valley Royal Hospital



EUROIMMUN AG
Sekisui Diagnostics
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Technology

view channel
Image:  The Becton Dickinson fluorescent activated cell sorter FACScan (Photo courtesy of the Albert Einstein College of Medicine).

Noninvasive Method Captures Circulating Tumor Cells

A clinically proven, noninvasive fluorescence virus-guided capture system of human colorectal circulating tumor cells (CTCs) from blood samples for genetic testing has been introduced. This noninvasive... Read more

Industry News

view channel

Beckman Coulter Acquires Siemens Healthcare Diagnostics’ Clinical Microbiology Business

Beckman Coulter (Brea, CA, USA), an indirect wholly-owned subsidiary of Danaher Corp. (Washington DC, MD, USA) has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (Chicago, IL, USA). The transaction is expected to close in the first quarter of 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.